AI across the Medtech lifecycle: From the bench to the balance sheet
To view this article on the Today’s Medical Developments Magazine website, click here.
The question facing medtech leaders today is no longer whether artificial intelligence (AI) belongs in their organization. With more than 1,250 FDA-authorized AI-enabled devices already in the market and a global AI healthcare market projected to exceed $45 billion by 2028, that debate is settled. The real question is how quickly companies can implement AI responsibly – and how well they understand where it creates value at each stage of the product lifecycle.
That’s the lens we brought to our recent webinar, The Value of AI in MedTech: From Start-up to Operational Excellence to M&A Exit, with Today’s Medical Developments: not AI as a concept, but AI as a practical, stage-by-stage value creator from early R&D through commercialization, manufacturing, and ultimately M&A exit.
Compressing the development timeline
The earliest and perhaps most profound impact of AI we’re seeing in medtech is in research and development. Virtual prototyping and simulation tools are replacing physical bench iterations, and AI-assisted regulatory document drafting is compressing timelines that once consumed months of engineering bandwidth. According to BCG, AI can reduce product design feasibility validation up to 70% and cut regulatory document drafting time by 50% to 90%. In an industry where speed to market is directly tied to competitive positioning and patent life, that’s not an incremental improvement – it’s a structural advantage.
Manufacturing gets smarter
On the manufacturing floor, AI is driving measurable gains in quality and efficiency. Machine vision systems are catching defects human inspectors miss, reducing manufacturing defect rates up to 30%. Predictive maintenance tools are identifying equipment failures before they disrupt production. And digital twins – virtual replicas of physical manufacturing lines – are enabling companies to test process changes in simulation before committing to costly physical trials.
The numbers behind these transformations are increasingly hard to ignore. BCG’s 2025 analysis found AI-first operating models in medtech can deliver approximately 10% revenue growth and 50% productivity uplift. One supply chain case documented a 15-percentage-point improvement in forecast accuracy, a 60% reduction in backorders, and $125 million in inventory released back to the balance sheet – capital that flows directly to enterprise value.
The human-AI partnership
What’s important to remember in all these AI-enabled improvements is humans are still needed! Throughout each of these stages, the most effective implementations share the common thread that AI augments human judgment rather than replacing it. Pattern recognition, high-volume data processing, and overnight virtual iteration are where AI excels. Clinical accountability, regulatory decision-making, and the relationship-driven dynamics of M&A remain firmly human domains. Companies that understand this distinction – and build their AI governance frameworks accordingly – are the ones seeing sustained adoption and measurable returns.
AI and the exit
For medtech leaders thinking about a future transaction, AI adoption is no longer just an operational story. Strategic acquirers are actively looking for companies with documented AI use cases, validated outcomes, and scalable recurring revenue models. Those doing so effectively are commanding meaningful valuation premiums. The need for a clear AI strategy has become imperative.
The takeaway for decision makers is straightforward: implement AI with rigor, measure its contribution to margin and revenue from day one, and build the narrative a future acquirer will want to see. The companies doing this today aren’t just improving operations. They’re building enterprise value, one use case at a time.
